Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study. - Tassone, Pierfrancesco; Di Martino, Maria Teresa; Arbitrio, Mariamena; Fiorillo, Lucia; Staropoli, Nicoletta; Ciliberto, Domenico; Cordua, Alessia; Scionti, Francesca; Bertucci, Bernardo; Salvino, Angela; Lopreiato, Mariangela; Thunarf, Fredrik; et al. (Journal of Hematology & Oncology, 2023)